GoodinDSRederATEbersGC. Survival in MS: a randomized cohort-study 21 years after the start of the pivotal IFNβ-1b trial. Neurology2012; 78: 1315–1322.
2.
ZauberAGWinawerSJO’BrienMJ. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med2012; 366: 687–696.
3.
AAN (American Academy of Neurology). Clinical Practice Guideline Process Manual, 2011 ed. St. Paul, MN: The American Academy of Neurology, 2011.
4.
PiantadosiS. Clinical Trials: A Methodologic Perspective (2nd Ed.). Hoboken, NJ: John Wiley & Sons Inc, 2005.
5.
PocockSJAssmannSEEnosLEKastenLE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med2002; 21: 2917–2930.
6.
GoodinDSTraboulseeAKnappertzV. Relationship between early clinical characteristics and long-term disability outcomes: 16-year follow-up of the pivotal IFNB-1b study in MS. J Neurol Neurosurg Psychiatry2012; 83: 282–287.
7.
SteinMSLiuYGrayOM. A randomized trial of high-dose vitamin D2 in relapsing–remitting multiple sclerosis. Neurology2011; 77: 1611–1618.
8.
RossACMansonJEAbramsSA. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metal2011; 96: 53–58.
